Aprotinin in the management of coagulopathy associated with amniotic fluid embolus

Pharmacotherapy

Volumn 26, Issue 5 I, 2006, Pages 689-693

  Stroup, Jeffrey S ^a   Haraway, G Davin ^b   Beal, J Martin ^b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF PHARMACY   (United States)

^b OKLAHOMA STATE UNIVERSITY   (United States)

Author keywords

Amniotic fluid embolus; Anaphylactoid syndrome of pregnancy; Aprotinin; Coagulopathy

Indexed keywords

ADRENALIN; APROTININ; CALCIUM; FRESH FROZEN PLASMA;

ADULT; AMNION FLUID EMBOLISM; ARTICLE; ASSISTED CIRCULATION; BLEEDING; BLOOD CLOTTING DISORDER; CARDIOPULMONARY ARREST; CASE REPORT; CESAREAN SECTION; CLINICAL FEATURE; CRYOPRECIPITATE; CYANOSIS; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; EMERGENCY SURGERY; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; HYPOTENSION; INTENSIVE CARE; MATERNAL MORTALITY; MORBIDITY; OXYGENATION; PLASMA TRANSFUSION; PREGNANCY COMPLICATION; SHOCK; THROMBOCYTE TRANSFUSION;

EID: 33646376889     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.5.689     Document Type: Article

References (19)

1. Davies S. Amniotic fluid embolus: a review of the literature. Can J Anaesth 2001;48(1):88-98.
2. Locksmith GJ. Amniotic fluid embolism. Obstet Gynecol Clin North Am 1999;26(3):435-44, vii.
3. Aurangzeb I, George L, Raoof S. Amniotic fluid embolism. Crit Care Clin 2004;20:643-50.
4. Tuffnell DJ. Amniotic fluid embolism. Curr Opin Obstet Gynecol 2003;15:119-22.
5. Green BT, Umana E. Amniotic fluid embolism. South Med J 2000;93(7):721-3.
6. Clark SL, Hankins GD, Dudley DA, Dildy GA, Porter TF. Amniotic fluid embolism: analysis of the national registry. Am J Obstet Gynecol 1995;172:1158-69.
7. Fletcher SJ, Parr MJ. Amniotic fluid embolism: a case report and review. Resuscitation 2000;43:141-6.
8. Taenaka N, Shimada Y, Kawai M, Yoshiya I, Kosaki G. Survival from DIC following amniotic fluid embolism. Anaesthesia 1981;36:389-93.
9. Levy JH. Hemostatic agents. Transfusion 2004;44:58S-62.
10. Wegner J. Biochemistry of serine protease inhibitors and their mechanisms of action: a review. J Extra Corpor Technol 2003;35(4):326-38.
11. Levy JH, Sypniewski E. Aprotinin: a pharmacologic overview. Orthopedics 2004;27(6 suppl):s653-8.
12. Holmes JH, Jones MF, Anderson RP, Knopes KD, Guyton SW, Hall RA. The use of micro-dose aprotinin with continuous infusion in coronary artery bypass surgery. J Cardiovasc Surg 1999;40(5):621-6.
13. Himmelreich G, Muser M, Neuhaus P, et al. Different aprotinin applications influencing hemostatic changes in orthotopic liver transplantation. Transplantation 1992;53:132-6.
14. Murkin JM, Haid GM, Beer KJ, et al. Aprotinin decreases exposure to allogeneic blood during primary unilateral total hip replacement. J Bone Joint Surg 2000;82-A(5):675-84.
15. Putterman C. Aprotinin therapy in septic shock [letter]. Acta Chir Scand 1989;155:367.
16. Porte RJ, Molenaar IQ, Begliomini B, et al. Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind study. The EMSALT study group. Lancet 2000;355(9212):1303-9.
17. Slunsky R. Inhibition of the thromboplastic activity of amniotic fluid with Trasylol [in German]. Gynakol Rundsch 1973;13(2):147-52.
18. Oney T, Schander K, Muller N, Fromm G, Lang N. Amniotic fluid embolism with coagulation disorder: a case report [in German]. Geburtshilfe Frauenheilkd 1982;42(1):25-8.
19. Greaff H, Holzmann K, Gokel JM, von Hugo R, Hafter R. Pathomechanisms, signs, symptoms and management of amniotic fluid embolism [in German]. Geburtshilfe Frauenheilkd 1978;38(11):887-94.